|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2008-6-19
|
|
pubmed:abstractText |
Natalizumab (Tysabri) is a new disease-modifying therapy that has been shown to be clinically effective in patients with relapsing-remitting multiple sclerosis (RRMS) and has been licensed for use in patients with highly active RRMS (HARRMS). These patients are those who experience higher relapse rates and faster disability progression than the general RRMS population.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
T
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1170-7690
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
617-27
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:18563952-Antibodies, Monoclonal,
pubmed-meshheading:18563952-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:18563952-Cost-Benefit Analysis,
pubmed-meshheading:18563952-Humans,
pubmed-meshheading:18563952-Interferon-beta,
pubmed-meshheading:18563952-Multiple Sclerosis,
pubmed-meshheading:18563952-Peptides,
pubmed-meshheading:18563952-Quality-Adjusted Life Years,
pubmed-meshheading:18563952-Recurrence
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.
|
|
pubmed:affiliation |
Heron Evidence Development, Letchworth, UK.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
